[A23-28] Dulaglutide (type 2 diabetes in children and adolescents) – Benefit assessment according to §35a Social Code Book V
Last updated 03.07.2023
Project no.:
A23-28
Commission:
Commission awarded on 31.03.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Digestion, metabolism and hormones
Children and adolescents aged 10 to 17 years with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
Insulin-naive children aged 10 to 17 years with type 2 diabetes mellitus who have not achieved sufficient glycaemic control with their ongoing drug treatment consisting of at least one blood-glucose lowering drug in addition to diet and exercise: added benefit not proven
Insulin-experienced children aged 10 to 17 years with type 2 diabetes mellitus who have not achieved sufficient glycaemic control with their ongoing insulin regimen in addition to diet and exercise: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A15-07 | Dulaglutide - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
| A20-09 | Dulaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V | Commission completed |